Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER for Major Depressive Disorder relapse prevention
NCT01085812Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of levomilnacipran in major depressive disorder (MDD), sponsored by Forest Laboratories. Started Mar 2010; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01085812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085812.